HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry - Wikidata - wikimedia - TriplyDB

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry

http://www.wikidata.org/entity/Q35554970

about

Screening for and verification of novel mutations associated with drug resistance in the HIV type 1 subtype B(') in China SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses Defining the fitness of HIV-1 isolates with dual/mixed co-receptor usage A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies.Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection.Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5 Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations Mutations in variable domains of the HIV-1 envelope gene can have a significant impact on maraviroc and vicriviroc resistance Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection.Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.Quantifying susceptibility of CD4+ stem memory T-cells to infection by laboratory adapted and clinical HIV-1 strains.Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution.Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.Quantifying CD4/CCR5 Usage Efficiency of HIV-1 Env Using the Affinofile System.Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.Simulations reveal that the HIV-1 gp120-CD4 complex dissociates via complex pathways and is a potential target of the polyamidoamine (PAMAM) dendrimer.Diversity matters in scientific publishing.

P2860

Q28485108-68DAE989-05CC-4CAB-A923-A248F4F81437 Q28742018-88A5C89C-72FD-4A86-8BE5-623FE317A535 Q30278577-72836325-95A4-4AE7-AB26-DD64861E7867 Q30654651-99F8094B-FA6F-4DB9-802D-209109D62A10 Q34058160-B7D39B62-E462-43E5-BE03-21CCCFE7635F Q34503200-7D9AFE53-0033-413A-A6D7-6AFB882731F0 Q34792976-26EB54E1-38BB-4EE7-BFF6-6465A638AABD Q36466404-D2F0B3BD-9FF0-43B4-8700-3E89907DFE63 Q36476641-744E1ECD-A4B3-40B8-B19F-2B9BE3C23F17 Q36607127-5CEE18C2-F711-4EF7-B83B-48DCAA5FB3DF Q36827946-57E1A209-20A9-4D0F-8326-DDD924CC5003 Q36980738-DD60966A-7118-44D1-A4B0-BA543D466EF9 Q37362368-E006245B-BB79-413B-A376-8AABE1CE3505 Q37390786-FA4B659B-80C3-451B-A1EA-5F4C53025FBD Q37611831-26CB323D-4B56-43D7-B993-2404423A8F94 Q37703084-61FEB266-AC1F-434A-8E9B-D41985C07F3F Q38196457-6B94B409-57B2-482D-AC57-73CFF75C4320 Q38803127-C8258738-FE20-45F8-BD2C-44E7493895F9 Q38808224-D3425700-7672-4ADC-9CB1-3433E521DD82 Q39361526-F652DE91-3FBF-4F42-86ED-321E276E86D3 Q42283259-02061916-2DCF-4308-9DC1-A4E7C8BE4752 Q42660338-09B5A286-DCF1-470C-AD16-BC95FC3847C9

P2860

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry

http://www.wikidata.org/entity/Q35554970

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

HIV-1 predisposed to acquiring ...... ilize MVC-bound CCR5 for entry

@ast

HIV-1 predisposed to acquiring ...... ilize MVC-bound CCR5 for entry

@en

type

label

HIV-1 predisposed to acquiring ...... ilize MVC-bound CCR5 for entry

@ast

HIV-1 predisposed to acquiring ...... ilize MVC-bound CCR5 for entry

@en

prefLabel

HIV-1 predisposed to acquiring ...... ilize MVC-bound CCR5 for entry

@ast

HIV-1 predisposed to acquiring ...... ilize MVC-bound CCR5 for entry

@en

P1433

Q35554970-BF4A6973-AEF8-46C7-B172-993377F0EAA9

P1476

Q35554970-0AE30B0A-EFB7-4DC2-9618-42467A5341BD

P2093

Q35554970-0B4096BC-7411-4E3F-BD33-8D0F191E6B60

Q35554970-361D091D-9093-474D-BD70-DD119B136508

Q35554970-677AB18C-7E1B-4577-9720-A000DEC6487F

Q35554970-8DB06E6B-DED3-4F15-A878-1419A1314A75

Q35554970-AAE4691E-DA00-4F3F-A4D3-3AA77BEC6151

Q35554970-B52ABEC2-2E30-46DF-860B-6146506185E9

Q35554970-E8542836-A0D1-4ADD-B077-E58FBD70A04C

P2860

Q35554970-1C249996-3EAE-45F8-813B-52C1099C6EDB

Q35554970-1F7C0DD6-C861-452B-9706-8978A314ADE9

Q35554970-3FB8C1A6-C793-4DDD-8861-77E85FAFD19D

Q35554970-40D81274-9FED-4B05-998C-29B7182B0940

Q35554970-4474BE33-8F99-4023-902A-89A923A671A5

Q35554970-50F1F2AE-203D-45BA-8D77-13136FCE5AA4

Q35554970-55CE8C3C-4322-4CF4-92A9-406F6FC93652

Q35554970-5A82CA42-8298-4DE9-922D-14A95E5EDD76

Q35554970-5E103D22-2276-492E-8C5E-684945441A18

Q35554970-5E3473F5-FDEC-44D5-8752-07FDF65F5516

P2888

Q35554970-B13A2B80-1D8A-4966-875C-25DD4764DDE4

P304

Q35554970-8857443E-5127-4A32-A992-1A6F835684CE

P31

Q35554970-0BEB3733-D199-4DBD-8FBB-B162C037B470

P356

Q35554970-6B79F5FD-99D9-4E74-8B26-572339A6FDC1

P478

Q35554970-5DAF55CE-8DD5-4C59-8AB9-0ECE2FA05BCE

P50

Q35554970-7B071789-618F-49BB-A31D-D13B1ABE0A00

Q35554970-AEAF7B48-2D05-4F7A-8EE6-05087E29E172

Q35554970-E6F6141B-C95A-4136-9634-2E588DE1AFCB

P577

Q35554970-51668665-4B92-43A8-A617-98AC30CC2051

P5875

Q35554970-DC3A4789-C7FB-4561-BA89-51F6C64FBB20

P6179

Q35554970-7DB270E1-0624-4DBE-85C3-B35F20103112

P698

Q35554970-F096618F-E9BD-4B15-B54F-ED2A376B75EC

P932

Q35554970-54388651-C775-49D0-A7DC-2E6CD4D4C4E7

P356

P1433

P1476

HIV-1 predisposed to acquiring ...... ilize MVC-bound CCR5 for entry

@en

P2093

Anne Ellett

http://www.w3.org/2001/XMLSchema#string

Becky Jubb

http://www.w3.org/2001/XMLSchema#string

Hamid Salimiseyedabad

http://www.w3.org/2001/XMLSchema#string

Martin R Jakobsen

http://www.w3.org/2001/XMLSchema#string

Melissa J Churchill

http://www.w3.org/2001/XMLSchema#string

Mike Westby

http://www.w3.org/2001/XMLSchema#string

Paul R Gorry

http://www.w3.org/2001/XMLSchema#string

P2860

Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry

HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.

HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells

Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages

P2888

P304

89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1742-4690-8-89

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Sharon R. Lewin

P577

2011-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51770691

http://www.w3.org/2001/XMLSchema#string

P6179

1051552927

http://www.w3.org/2001/XMLSchema#string

P698

22054077

http://www.w3.org/2001/XMLSchema#string

P932

3217884

http://www.w3.org/2001/XMLSchema#string